Sector News

Atara hires ex-Genentech SVP to lead global R&D

May 7, 2018
Life sciences

Atara Biotherapeutics has named Dietmar Berger, M.D., Ph.D., as its global head of R&D. Berger joins after seven years at Roche’s Genentech, during which time he had a hand in the approval of drugs including PD-L1 checkpoint inhibitor Tecentriq.

Genentech hired Berger late in 2011 to oversee HER2 breast cancer programs and promoted him to the position of SVP, global clinical development for its oncology and hematology group a couple of years later. The positions gave Berger a role in many of the cancer drugs that have come down the pipeline at Roche in recent years, including Alecensa, Gazyva and Tecentriq.

Berger inherits a different set of challenges and priorities at Atara, which is closing in on a European approval of cytotoxic T lymphocyte ATA129 while putting the drug through a clutch of clinical trials. But Berger’s new employer thinks the experience he gained at Genentech will translate to Atara.

“His deep experience building high-performing teams and strategic leadership of cancer immunotherapy development will help us shape the future of our innovative T-cell immunotherapy pipeline and technology platform,” Atara CEO Isaac Ciechanover, M.D., said in a statement.

Berger joins Atara at a time when the second iteration of the biotech is reaching maturity. Atara spun out of Amgen, where Berger began his career, in 2012 and made a kidney disease candidate its top priority shortly thereafter. That plan went awry in 2015 when the kidney candidate flunked a midphase study, forcing Atara to shift gears and step up its focus on oncology.

Two years later, the switch has begun to pay off as development of ATA129 has entered the endgame. Full phase 3 readouts are still to come but Atara thinks it can package up the data generated to date to support a filing for conditional approval in Europe this year.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach